Its deal with the US-based AI-driven drug design and development company will see Cloud design novel small-molecule agents to GSK-specified targets. Ed Addison, CEO of Cloud Pharmaceuticals ...
GlaxoSmithKline is investing in artificial ... The company claims to be the first to automate drug design, surpassing conventional approaches. It says novel compounds prioritised for synthesis ...
The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback